亞洲資產(08025.HK)擬“10合1”並股及買賣單位更改為每手3000股
格隆匯2月10日丨亞洲資產(08025.HK)宣佈,董事會建議實行股份合併,擬“10合1”合併股份。待股份合併生效後,董事會亦擬將在聯交所買賣的股份的每手買賣單位由每手2,000股現有股份改為每手3,000股合併股份。
緊隨股份合併生效後,將實行股本削減及股份拆細,據此公司已發行股本將透過註銷繳足股本(以每股當時已發行合併股份註銷0.9港元為限)予以削減,致使每股已發行合併股份面值將由1.0港元減至0.1港元;及緊隨股本削減後,每股面值1.0港元法定但未發行合併股份各自將拆細為10股每股面值0.1港元的新股份。公司將因股本削減而產生約1.8億港元的進賬金額。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.